SUPAC level 3 changes for MR formulations [Regulatives / Guidelines]

posted by jag009  – NJ, 2019-10-22 21:31  – Posting: # 20715
Views: 341

Hi,

» 1. IR product if we change the manufacturing site, do we need to perform BE study as suggested in SUPAC guidance for IR? or it would be okay to justify based on in vitro data?

Did you read the SUPAC guidance for IR?

» 2. For MR product SUPAC MR guidance is not clear for any requirement of conducting BE study. where as we do perform Fasting for such changes in manufacturing site change. are we doing correct?

I dont follow. Are you asking if the study should be a fasted study?

J

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,987 posts in 4,229 threads, 1,374 registered users;
online 18 (0 registered, 18 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 19:41 CET

To know the history of science is to recognize the mortality
of any claim to universal truth.    Evelyn Fox Keller

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5